PreveCeutical Signs Research and Development Agreement with UniQuest Pty Limited for Development of Caribbean Blue Scorpion Venom-Derived Natural & Synthetic Peptides

Spotlight Companies |

PreveCeutical Medical Inc. a health and wellness company focused on utilizing nature and science for the benefit of health-conscious consumers, is pleased to announce that it signed a research and option agreement (the "Agreement") with UniQuest Pty Limited (“UniQuest”) for conducting a research program (the "Research Program") for the development of Scorpion Venom-Derived Natural & Synthetic Peptides. UniQuest is the main commercialisation company for the University of Queensland (“UQ”).

PMI has an interest in the preventative health sector and is developing products derived from Caribbean Blue Scorpion Venom for the nutraceutical and eventual pharmaceutical market. This includes the CellB9 Immune System Booster product, which contains peptides that are obtained from the Caribbean Blue Scorpion. In collaboration with UniQuest, PMI would like to identify the active components (peptides) that are providing the immune boosting and tumor selective painting properties, access synthetic versions of the active peptides as an alternative to relying on milking the Caribbean Blue Scorpions, and ultimately identify other therapeutic applications for the Blue Scorpion Venom and/or active peptides.

The duration of the proposed Research Program is up to twenty-four (24) months and will encompass the identification of milked Caribbean Blue Scorpion Venom-containing peptides, chemical synthesis of natural and synthetic peptide variants stabilised with UQ’s proprietary chemistry, followed by screening the peptides in various disease models of interest to PMI and UniQuest. The proposed Research Program will be carried out in three (3) phases.

Under the Agreement, intellectual property arising from the carrying out of, results developed during, or created by the Research Program (excluding any improvements to existing intellectual property used in the Research Program) will be owned by PMI. At any time during the Research Program or for an agreed period after the completion of the Research Program, the Agreement provides PMI with an option to negotiate with UniQuest for a license (the “Licence”) to use UniQuest’s intellectual property for the commercialisation of blue scorpion venom derived products by PMI. The granting of the license is subject to the parties negotiating the terms of the License and entering into a definitive licensing agreement.

“Working with UniQuest and the University of Queensland on this research program presents PMI with unique opportunities towards developing products that promote good health and wellness. Wellness products developed from Scorpion Venom-Derived Natural & Synthetic Peptides have the potential to be utilised in a number of therapeutic applications including boosting immune systems”,said Stephen Van Deventer, PMI’s Chairman and Chief Executive Officer.

Information on these projects will be presented by Dr. Makarand Jawadekar, PMI’s Chief Science Officer, and Dr. Harendra (Harry) Parekh, of the University of Queensland’s School of Pharmacy, at PMI’s presentation on April 27, 2017.

Presentation Information:

Venue: The Fairmont Waterfront Hotel (900 Canada Pl, Vancouver, BC V6C 3L5), Malaspina Room

Date: Thursday, April 27, 2017



Time: 1:30 p.m. PDT to 6:00 p.m. PDT

Confirm your attendance, register by clicking here: https://preveceutical-presentation-2017.eventbrite.ca/

Update on Previously Announced Amalgamation and Financing

The non-brokered private placement of up to 10 million units for minimum gross proceeds of at least $1 million and maximum gross proceeds of up to $5 million (the "Financing") being conducted by Carrara Exploration Corp. (CSE:CAA) ("Carrara"), pursuant to a previously announced amalgamation agreement, is ongoing. The amalgamation agreement provides for the acquisition of PMI by Carrara by way of a three-cornered amalgamation and a reverse take-over of Carrara by PMI. A copy of the news release announcing the Financing and a copy of the amalgamation agreement were posted on Carrara’s profile on the System for Electronic Document Analysis and Retrieval (SEDAR)’s website on March 23, 2017, and can be accessed at www.sedar.com.

About UniQuest Pty Ltd.

UniQuest is the main commercialization company of UQ, specialising in the commercialisation of intellectual property, research outcomes and expertise. UniQuest delivers commercialization outcomes which provide impact for business, the environment, global communities and society as a whole. UniQuest benchmarks in the top 10 percent globally for university-based technology transfer. UQ innovations licenced by UniQuest are now generating annual sales of over $3 billion. For example, UQ superconductor technology, through licensing arrangements, is used in two-thirds of the world’s MRIs and more than 80 million doses of the life-saving Gardasil® cervical cancer vaccine, patented by UniQuest in 1991, have been distributed throughout 121 countries, including 72 developing countries.

On Behalf of the Board of Directors,

Stephen Van Deventer
Chairman & CEO

Disclosure: In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
CAA:CNX Carrara Exploration Corp n/a n/a n/a n/a

Comments

Emerging Growth

Liberty One Lithium Corp

Liberty One Lithium Corp is a mineral exploration company engaged in acquisition and development of high grade lithium brine deposits.

Private Markets

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…